JP7424636B2 - 微生物感染症の治療および／または予防用グルコン酸誘導体 - Google Patents
微生物感染症の治療および／または予防用グルコン酸誘導体 Download PDFInfo
- Publication number
- JP7424636B2 JP7424636B2 JP2020519028A JP2020519028A JP7424636B2 JP 7424636 B2 JP7424636 B2 JP 7424636B2 JP 2020519028 A JP2020519028 A JP 2020519028A JP 2020519028 A JP2020519028 A JP 2020519028A JP 7424636 B2 JP7424636 B2 JP 7424636B2
- Authority
- JP
- Japan
- Prior art keywords
- vaginal
- pharmaceutical composition
- infection
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 103
- 238000011282 treatment Methods 0.000 title claims description 26
- 230000002265 prevention Effects 0.000 title claims description 17
- 230000000813 microbial effect Effects 0.000 title description 34
- 150000001875 compounds Chemical class 0.000 claims description 89
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims description 48
- 208000035143 Bacterial infection Diseases 0.000 claims description 28
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 28
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 28
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 28
- 239000000182 glucono-delta-lactone Substances 0.000 claims description 28
- 229960003681 gluconolactone Drugs 0.000 claims description 28
- 235000014655 lactic acid Nutrition 0.000 claims description 28
- 239000004310 lactic acid Substances 0.000 claims description 26
- 241000194017 Streptococcus Species 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 208000035473 Communicable disease Diseases 0.000 claims description 17
- 201000004624 Dermatitis Diseases 0.000 claims description 17
- 239000004599 antimicrobial Substances 0.000 claims description 15
- 150000002596 lactones Chemical class 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 208000003322 Coinfection Diseases 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 8
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000037006 agalactosis Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000207202 Gardnerella Species 0.000 claims description 6
- 208000005107 Premature Birth Diseases 0.000 claims description 5
- 206010046914 Vaginal infection Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000002949 hemolytic effect Effects 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 4
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 206010003399 Arthropod bite Diseases 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 206010008323 cervicitis Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000522 vaginal cream Substances 0.000 claims description 3
- 239000000029 vaginal gel Substances 0.000 claims description 3
- 239000006213 vaginal ring Substances 0.000 claims description 3
- 239000006216 vaginal suppository Substances 0.000 claims description 3
- 239000000003 vaginal tablet Substances 0.000 claims description 3
- 206010002515 Animal bite Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 201000000297 Erysipelas Diseases 0.000 claims description 2
- 206010062488 Erythema migrans Diseases 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 206010017553 Furuncle Diseases 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 206010022013 Ingrowing nail Diseases 0.000 claims description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 208000004374 Tick Bites Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 229940044959 vaginal cream Drugs 0.000 claims description 2
- 239000000259 vaginal foam Substances 0.000 claims description 2
- 229940044950 vaginal gel Drugs 0.000 claims description 2
- 229940098946 vaginal ointment Drugs 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 229940120293 vaginal suppository Drugs 0.000 claims description 2
- 229940044977 vaginal tablet Drugs 0.000 claims description 2
- 208000010484 vulvovaginitis Diseases 0.000 claims description 2
- 206010061126 Escherichia infection Diseases 0.000 claims 1
- 206010073931 Genital herpes simplex Diseases 0.000 claims 1
- 206010061182 Genitourinary tract infection Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000001688 Herpes Genitalis Diseases 0.000 claims 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 claims 1
- 244000309698 Mucor paronychius Species 0.000 claims 1
- 208000009675 Perioral Dermatitis Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 1
- 208000020612 escherichia coli infection Diseases 0.000 claims 1
- 201000004946 genital herpes Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000003606 oligomerizing effect Effects 0.000 claims 1
- 230000000379 polymerizing effect Effects 0.000 claims 1
- 229940044952 vaginal foam Drugs 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 92
- 235000012208 gluconic acid Nutrition 0.000 description 60
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 59
- 239000000174 gluconic acid Substances 0.000 description 51
- 241000222122 Candida albicans Species 0.000 description 47
- 229950006191 gluconic acid Drugs 0.000 description 40
- 230000032770 biofilm formation Effects 0.000 description 37
- 206010017533 Fungal infection Diseases 0.000 description 33
- 208000031888 Mycoses Diseases 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 31
- 239000002609 medium Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 24
- 229960000448 lactic acid Drugs 0.000 description 23
- 239000000872 buffer Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 17
- 230000002538 fungal effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 206010007134 Candida infections Diseases 0.000 description 13
- 125000001931 aliphatic group Chemical group 0.000 description 13
- 241001148470 aerobic bacillus Species 0.000 description 12
- 235000015165 citric acid Nutrition 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241000233866 Fungi Species 0.000 description 10
- 229940121375 antifungal agent Drugs 0.000 description 10
- 201000003984 candidiasis Diseases 0.000 description 10
- 229960004106 citric acid Drugs 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 241000218492 Lactobacillus crispatus Species 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 229940095731 candida albicans Drugs 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241001324870 Lactobacillus iners Species 0.000 description 7
- 208000002474 Tinea Diseases 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 239000003429 antifungal agent Substances 0.000 description 6
- 208000032343 candida glabrata infection Diseases 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 244000197813 Camelina sativa Species 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 241000222126 [Candida] glabrata Species 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 4
- -1 afloxam Chemical compound 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- 206010012504 Dermatophytosis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- 206010024774 Localised infection Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001460074 Microsporum distortum Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000223238 Trichophyton Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 208000007287 cheilitis Diseases 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000024386 fungal infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- 208000008158 Chorioamnionitis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000003928 Malus coronaria Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 125000000422 delta-lactone group Chemical group 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000000457 gamma-lactone group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001633064 Atopobium vaginae Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010052100 Beta haemolytic streptococcal infection Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 101000981881 Brevibacillus parabrevis ATP-dependent glycine adenylase Proteins 0.000 description 1
- 101000981889 Brevibacillus parabrevis Linear gramicidin-PCP reductase Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000675278 Candida albicans SC5314 Species 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- QXKAIJAYHKCRRA-UHFFFAOYSA-N D-lyxonic acid Natural products OCC(O)C(O)C(O)C(O)=O QXKAIJAYHKCRRA-UHFFFAOYSA-N 0.000 description 1
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000034801 Enterobacteriaceae Infections Diseases 0.000 description 1
- 206010014889 Enterococcal infections Diseases 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000258241 Mantis Species 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027205 Meningitis candida Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 241000215320 Mobiluncus sp. Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 241000985659 Penstemon centranthifolius Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 241000611831 Prevotella sp. Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241001468181 Streptococcus sp. 'group C' Species 0.000 description 1
- 241000194005 Streptococcus sp. 'group G' Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- YJHDFAAFYNRKQE-YHPRVSEPSA-L disodium;5-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[(e)-2-[4-[[4-anilino-6-[bis(2-hydroxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].N=1C(NC=2C=C(C(\C=C\C=3C(=CC(NC=4N=C(N=C(NC=5C=CC=CC=5)N=4)N(CCO)CCO)=CC=3)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)=NC(N(CCO)CCO)=NC=1NC1=CC=CC=C1 YJHDFAAFYNRKQE-YHPRVSEPSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009105 vegetative growth Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyesters Or Polycarbonates (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195192.4 | 2017-10-06 | ||
| EP17195192 | 2017-10-06 | ||
| PCT/EP2018/077129 WO2019068862A1 (en) | 2017-10-06 | 2018-10-05 | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536862A JP2020536862A (ja) | 2020-12-17 |
| JP2020536862A5 JP2020536862A5 (enExample) | 2021-11-11 |
| JP7424636B2 true JP7424636B2 (ja) | 2024-01-30 |
Family
ID=60185986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519028A Active JP7424636B2 (ja) | 2017-10-06 | 2018-10-05 | 微生物感染症の治療および／または予防用グルコン酸誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11612584B2 (enExample) |
| EP (1) | EP3691625B1 (enExample) |
| JP (1) | JP7424636B2 (enExample) |
| KR (1) | KR102650182B1 (enExample) |
| CN (1) | CN111182895B (enExample) |
| AU (1) | AU2018346361B2 (enExample) |
| BR (1) | BR112020006931A2 (enExample) |
| CA (1) | CA3078451A1 (enExample) |
| CL (1) | CL2020000859A1 (enExample) |
| EA (1) | EA202090750A1 (enExample) |
| ES (1) | ES3017694T3 (enExample) |
| HU (1) | HUE070746T2 (enExample) |
| IL (1) | IL273297B2 (enExample) |
| MX (1) | MX2020003660A (enExample) |
| MY (1) | MY205944A (enExample) |
| PH (1) | PH12020550222A1 (enExample) |
| PL (1) | PL3691625T3 (enExample) |
| SG (1) | SG11202002494WA (enExample) |
| UA (1) | UA126590C2 (enExample) |
| WO (1) | WO2019068862A1 (enExample) |
| ZA (1) | ZA202001605B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019068862A1 (en) | 2017-10-06 | 2019-04-11 | Gedea Biotech Ab | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS |
| MA56011A (fr) | 2019-04-05 | 2022-04-06 | Gedea Biotech Ab | Formulation de comprimé vaginal |
| CN114751878B (zh) * | 2022-03-29 | 2023-06-16 | 青岛农业大学 | 一种BcTol1基因靶向剂及其应用 |
| EP4731203A1 (en) * | 2023-06-22 | 2026-04-29 | Gedea Biotech AB | Compositions for promoting growth of lactobacillus crispatus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007077152A (ja) | 2005-09-12 | 2007-03-29 | Mcneil Ppc Inc | 膣のｐＨを低下させるための組成物および方法 |
| JP2007077150A (ja) | 2005-09-12 | 2007-03-29 | Mcneil Ppc Inc | 酸−酸緩衝系を含有する無水組成物 |
| US20080058421A1 (en) | 2006-09-05 | 2008-03-06 | John Alex Lopes | Compositions for cleaning and disinfecting nasal tract and sinus cavity |
| JP2017501741A (ja) | 2013-11-08 | 2017-01-19 | スーヂョウ オーセル バイオ−ファーム カンパニー、リミテッド | ラクトバチルス・クリスパタスおよびその応用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1278868B1 (it) | 1995-10-27 | 1997-11-28 | Sanitaria Scaligera Spa | Metodo per l'ottenimento di un materiale riassorbibile atto ad essere utilizzato come elemento di rivestimento per la prevenzione di |
| AUPP839499A0 (en) | 1999-01-29 | 1999-02-25 | Australian National University, The | A method for controlling plant pathogens, and agents useful for same |
| JP3745612B2 (ja) | 2000-10-31 | 2006-02-15 | 西川ゴム工業株式会社 | ポリヒドロキシカルボン酸の製造方法 |
| US20060172007A1 (en) * | 2001-05-01 | 2006-08-03 | Nawaz Ahmad | Compositions and methods for reducing vaginal pH |
| US20030017207A1 (en) * | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
| US7569530B1 (en) | 2003-06-20 | 2009-08-04 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| CA2487270C (en) | 2002-06-21 | 2010-10-26 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US7547454B2 (en) * | 2002-11-07 | 2009-06-16 | Shyam K Gupta | Hydroxy acid complexes for antiaging and skin renovation |
| US20040126369A1 (en) * | 2002-12-30 | 2004-07-01 | Richard Payne | Delivery of peroxide-generating enzymes to the vaginal tract |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
| US20050271711A1 (en) | 2004-04-26 | 2005-12-08 | The Procter & Gamble Company | Therapeutic antimicrobial compositions and methods |
| US20070059278A1 (en) | 2005-09-12 | 2007-03-15 | Nawaz Ahmad | Anhydrous composition containing an acid-acid buffer system |
| WO2008108834A2 (en) * | 2006-11-09 | 2008-09-12 | Northwestern University | Inhibitors of the mevalonate pathway of streptococcus pneumoniae |
| JP2008283893A (ja) * | 2007-05-16 | 2008-11-27 | Sumitomo Chemical Co Ltd | 家禽用コクシジウム感染抑制剤及びそれを用いたコクシジウム感染抑制方法 |
| US20100285095A1 (en) * | 2009-05-05 | 2010-11-11 | Kimberly Ann Nemeth | Hygiene Article Having Calcium Sugar Acid Salt |
| CN102070774B (zh) | 2010-11-25 | 2012-08-22 | 华南师范大学 | 单糖或其糖醇与乳酸的共聚物的制备方法 |
| EP2704694A4 (en) | 2011-05-02 | 2014-11-19 | Aptalis Pharmatech Inc | RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY |
| DK178786B1 (en) * | 2015-03-11 | 2017-02-06 | Dantrace-Danfeed Ivs | Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus |
| MX382396B (es) * | 2016-04-06 | 2025-03-13 | Gedea Biotech Ab | Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales. |
| CA3040422A1 (en) | 2016-10-13 | 2018-04-19 | Catalent U.K. Swindon Zydis Limited | Lyophilized pharmaceutical compositions for vaginal delivery |
| KR101841976B1 (ko) | 2017-06-07 | 2018-05-14 | 조영진 | 식물 추출물을 포함하는 항진균 및 항균 조성물 |
| WO2019068862A1 (en) | 2017-10-06 | 2019-04-11 | Gedea Biotech Ab | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS |
| MA56011A (fr) | 2019-04-05 | 2022-04-06 | Gedea Biotech Ab | Formulation de comprimé vaginal |
-
2018
- 2018-10-05 WO PCT/EP2018/077129 patent/WO2019068862A1/en not_active Ceased
- 2018-10-05 KR KR1020207010202A patent/KR102650182B1/ko active Active
- 2018-10-05 US US16/753,899 patent/US11612584B2/en active Active
- 2018-10-05 HU HUE18788687A patent/HUE070746T2/hu unknown
- 2018-10-05 ES ES18788687T patent/ES3017694T3/es active Active
- 2018-10-05 PL PL18788687.4T patent/PL3691625T3/pl unknown
- 2018-10-05 JP JP2020519028A patent/JP7424636B2/ja active Active
- 2018-10-05 CA CA3078451A patent/CA3078451A1/en active Pending
- 2018-10-05 CN CN201880065162.XA patent/CN111182895B/zh active Active
- 2018-10-05 EP EP18788687.4A patent/EP3691625B1/en active Active
- 2018-10-05 AU AU2018346361A patent/AU2018346361B2/en active Active
- 2018-10-05 SG SG11202002494WA patent/SG11202002494WA/en unknown
- 2018-10-05 IL IL273297A patent/IL273297B2/en unknown
- 2018-10-05 UA UAA202002422A patent/UA126590C2/uk unknown
- 2018-10-05 MX MX2020003660A patent/MX2020003660A/es unknown
- 2018-10-05 EA EA202090750A patent/EA202090750A1/ru unknown
- 2018-10-05 BR BR112020006931-0A patent/BR112020006931A2/pt active IP Right Grant
- 2018-10-05 MY MYPI2020001657A patent/MY205944A/en unknown
-
2020
- 2020-03-13 ZA ZA2020/01605A patent/ZA202001605B/en unknown
- 2020-03-31 CL CL2020000859A patent/CL2020000859A1/es unknown
- 2020-04-06 PH PH12020550222A patent/PH12020550222A1/en unknown
-
2023
- 2023-02-02 US US18/163,321 patent/US12226396B2/en active Active
-
2025
- 2025-01-08 US US19/013,187 patent/US20250144070A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007077152A (ja) | 2005-09-12 | 2007-03-29 | Mcneil Ppc Inc | 膣のｐＨを低下させるための組成物および方法 |
| JP2007077150A (ja) | 2005-09-12 | 2007-03-29 | Mcneil Ppc Inc | 酸−酸緩衝系を含有する無水組成物 |
| US20080058421A1 (en) | 2006-09-05 | 2008-03-06 | John Alex Lopes | Compositions for cleaning and disinfecting nasal tract and sinus cavity |
| JP2017501741A (ja) | 2013-11-08 | 2017-01-19 | スーヂョウ オーセル バイオ−ファーム カンパニー、リミテッド | ラクトバチルス・クリスパタスおよびその応用 |
Non-Patent Citations (2)
| Title |
|---|
| New Food Industry，Vol.47, No.3，2005年，p.45-54 |
| Research in Microbiology，2014年，Vol.165，p.549-558 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202001605B (en) | 2023-12-20 |
| IL273297B1 (en) | 2024-02-01 |
| US11612584B2 (en) | 2023-03-28 |
| UA126590C2 (uk) | 2022-11-02 |
| EP3691625C0 (en) | 2025-02-19 |
| PL3691625T3 (pl) | 2025-05-12 |
| AU2018346361B2 (en) | 2024-07-25 |
| IL273297A (en) | 2020-04-30 |
| BR112020006931A2 (pt) | 2020-10-06 |
| EP3691625B1 (en) | 2025-02-19 |
| HUE070746T2 (hu) | 2025-07-28 |
| ES3017694T3 (en) | 2025-05-13 |
| EP3691625A1 (en) | 2020-08-12 |
| WO2019068862A1 (en) | 2019-04-11 |
| US20200253925A1 (en) | 2020-08-13 |
| AU2018346361A1 (en) | 2020-05-14 |
| US12226396B2 (en) | 2025-02-18 |
| US20230181523A1 (en) | 2023-06-15 |
| CL2020000859A1 (es) | 2020-10-02 |
| PH12020550222A1 (en) | 2021-02-15 |
| MX2020003660A (es) | 2020-08-03 |
| IL273297B2 (en) | 2024-06-01 |
| JP2020536862A (ja) | 2020-12-17 |
| SG11202002494WA (en) | 2020-04-29 |
| CN111182895B (zh) | 2024-05-14 |
| KR102650182B1 (ko) | 2024-03-21 |
| CN111182895A (zh) | 2020-05-19 |
| CA3078451A1 (en) | 2019-04-11 |
| EA202090750A1 (ru) | 2020-11-11 |
| MY205944A (en) | 2024-11-21 |
| US20250144070A1 (en) | 2025-05-08 |
| KR20200060413A (ko) | 2020-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226396B2 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| CA2819632C (en) | Vaginal composition based on alkyl polyglucosides | |
| EA002920B1 (ru) | Фармацевтические композиции на основе тизоксанида и нитазоксанида | |
| JP6967785B2 (ja) | 膣真菌感染症の治療のためのグルコノデルタ−ラクトン | |
| KR101296009B1 (ko) | 질 및 외음 감염의 예방 및/또는 치료 방법 | |
| HK40029669B (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| HK40029669A (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| JP2025151411A (ja) | 細菌性膣症の抑制剤、細菌性膣症関連細菌のオートインデューサー－２阻害剤、細菌性膣症関連細菌のバイオフィルム形成の抑制剤、細菌性膣症関連細菌に対する抗菌薬抗菌力の増強剤、及び当該抗菌力の増強方法 | |
| KR20260006643A (ko) | 세균의 증식 억제제, 그것을 포함하는 화장품, 의약 부외품 및 의약 조성물, 그리고 세균의 증식 억제 방법 | |
| JP2019521134A (ja) | 性感染症用組成物 | |
| BR112018070370B1 (pt) | Glucono delta-lactona para tratamento de candidíase vulvovaginal | |
| EP4731203A1 (en) | Compositions for promoting growth of lactobacillus crispatus | |
| HK40000183B (en) | Glucono delta-lactone for treatment of vaginal fungal infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20200416 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211004 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221011 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230411 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230711 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230911 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7424636 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |